]>
IRCT20101130005280N31 IRCT 2019-12-21 Mashhad University of Medical Sciences Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophrenia Study of the effect of Atomoxetine in comparison with placebo on cognitive symptoms in patients with schizophrenia 2019-11-22 anticipated 42 Complete https://irct.ir/trial/43061 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block Randomization We can create a block to assign sample numbers equally to each group. If block size is two, we can make two possible sequences of AB and BA. based on arrangement allocated participants to a treatment and control groups with sealed envelope, Blinding description: Patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware of the type of interventions. Therefore, the trial will be run as triple blind. 2-3 schizophrenia. Intervention 1: Intervention group: Patients are given 40 mg of automoxetine is given daily by Tadbir Kala Jam Pharmaceutical Company for 4 weeks and then 80 mg for another 4 weeks. Intervention 2: Control group is given placebo according to the same protocol. Placebo is manufactured and prepared by the Mashhad School of Pharmacy. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information
public Dr Fatemeh Behdani
Ibn-e-Sina Hospita, Bu-Ali Sq., Amel Blvd., Mashhad.
Mashhad Iran (Islamic Republic of) 919583134 +98 51 3711 2701 behdanif@mums.ac.ir Mashhad University of Medical Sciences scientific Dr Fatemeh Behdani
Ibn-e-Sina Hospita, Bu-Ali Sq., Amel Blvd., Mashhad.
Mashhad Iran (Islamic Republic of) 919583134 +98 51 3711 2701 behdanif@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) 2nd Generation Antipsychotic Drug use Lack of dementia Not taking other medicines (except anticholinergics and benzodiazepines) No pregnancy or breastfeeding There is no recent history of drugs (except nicotine) schizophrenic patients during partial recovery 18 years 60 years Both Drug side effects including: abdominal discomfort, loss of appetite resulting in weight loss, dizziness, irritability and mood swings Occurrence of drug interactions with patient medications F00-F98 اختلالات رفتاری و روانی Treatment - Drugs Other Intervention group: Patients are given 40 mg of automoxetine is given daily by Tadbir Kala Jam Pharmaceutical Company for 4 weeks and then 80 mg for another 4 weeks. Control group is given placebo according to the same protocol. Placebo is manufactured and prepared by the Mashhad School of Pharmacy Cognitive function. Timepoint: Before intervention, end of first and second. Method of measurement: PANSS،Wisconsin، Stroop، Digit Span Questionier. Mashhad University of Medical Sciences Approved 2019-04-16 Ethics committee of Mashhad University of Medical Sciences Building Ghoreshi, Central Organization of Mashhad University of Medical Sciences, Daneshgah Avenue, Mashhad, Iran. mashhad Razavi Khorasan Iran (Islamic Republic of)